Updated results from the phase III Vibrance-MG study, presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting, indicate that nipocalimab (Imaavy) continues to benefit adolescents with generalized myasthenia gravis after two years of treatment. The drug works by lowering the abnormal antibody levels that disrupt nerve-muscle communication in this autoimmune condition, without causing a clinically significant drop in overall immunity.
According to investigator Jonathan Strober, MD, of UCSF Benioff Children's Hospital, patients showed meaningful reductions on both the Quantitative Myasthenia Gravis scale and the MG-ADL activities of daily living scale, and those improvements were maintained over the longer term. A particularly encouraging finding was that most participants could reduce their steroid dose or stop steroids entirely, which is important because steroids carry substantial side effects.
No new safety concerns emerged during extended follow-up. While infections were among the more common side effects, none were serious enough to force patients off the drug permanently. One patient briefly paused treatment but was able to restart. Strober noted that because many participants were in later adolescence, the data support the possibility that the drug will continue to work as these patients transition to adult care, though he also pointed out that pediatric patients sometimes experience higher remission rates, making long-term outcomes worth watching.